Key facts
- This page summarizes Bain Capital Life Sciences Investors, LLC's Form 3 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Dec 2023, 17:09.
Bain Capital Life Sciences Investors, LLC - 29 Dec 2023 Form 3 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NAMS
- Reported as of
- 29 Dec 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Dec 2023, 17:09:49 UTC
- Prior SEC filing
- 30 May 2023
- Next SEC filing
- 12 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- See signatures included in Exhibit 99.1
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Bain Capital Life Sciences Investors, LLC filed Form 3 for NewAmsterdam Pharma Co N.V. (NAMS) on 29 Dec 2023.
Change
- Previous filing in this sequence was filed on 30 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,473,913
- Date
- 29 Dec 2023
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NAMS
holding
Derivative
Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Dec 2023
- Ownership
- See footnotes
- Underlying class
- Ordinary Shares
- Underlying amount
- 100,000
- Exercise price
- $11.50
- Footnotes
- F2, F3, F4, F5, F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Represents 5,376,356 Ordinary Shares held directly by BCLS Fund III Investments, LP ("BCLS Fund III"), 4,797,557 Ordinary Shares held directly by BCLS II Investco, LP ("BCLS II Investco"), 267,429 Ordinary Shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II") and 32,571 Ordinary Shares held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund III, BCLS II Investco and BCLS Fund II, the "Bain Capital Life Sciences Entities").
Footnote F2
Represents a warrant to purchase 89,143 Ordinary Shares held directly by BCLS Fund II and a warrant to purchase 10,857 Ordinary Shares held directly by BCIPLS.
Footnote F3
Bain Capital Life Sciences III General Partner LLC ("BCLS III GP") is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III GP"), which is the general partner of BCLS Fund III. As a result, each of BCLS III GP, BCLS III and BCLS Fund III GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III. Each of BCLS III GP, BCLS III and BCLS Fund III GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F4
Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F5
BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F6
Boylston Coinvestors, LLC is the general partner of BCIPLS.
Footnote F7
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of each of BCLS III GP and BCLSI II and governs the investment strategy and decision making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.